{
    "clinical_study": {
        "@rank": "31651", 
        "arm_group": [
            {
                "arm_group_label": "Lisinopril Tablets 40 mg", 
                "arm_group_type": "Experimental", 
                "description": "Lisinopril Tablets 40 mg of Ipca Laboratories Limited, India"
            }, 
            {
                "arm_group_label": "Zestril\u00ae (Lisinopril) 40 mg Tablets", 
                "arm_group_type": "Active Comparator", 
                "description": "Zestril\u00ae (Lisinopril) 40 mg Tablets of AstraZeneca Pharmaceuticals LP USA"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized, balanced, open Label, two-treatment, two-period, two-sequence, single\n      dose, crossover pivotal study. The purpose of this study is to assess the bioequivalence\n      between Test Product and the corresponding Reference Product under fasting condition in\n      normal, healthy, adult, male and female human subjects."
        }, 
        "brief_title": "Bioequivalence Study of Lisinopril Tablets 40 mg Under Fasting Condition", 
        "completion_date": {
            "#text": "August 2012", 
            "@type": "Actual"
        }, 
        "condition": "Fasting", 
        "detailed_description": {
            "textblock": "Objective of this pivotal study was to assess the bioequivalence between Test Product:\n      Lisinopril Tablets 40 mg of Ipca Laboratories Limited, India and the corresponding Reference\n      Product: Zestril\u00ae (Lisinopril) 40 mg Tablets of AstraZeneca Pharmaceuticals LP USA, under\n      fasting condition in normal, healthy, adult, male and female human subjects in a randomized\n      crossover study.\n\n      The study was conducted with 40 healthy adult subjects. In each study period, a single 40 mg\n      dose of either test or reference was administered to the subjects as per the randomization\n      schedule in each study period with about 240 mL of water at ambient temperature in sitting\n      position.\n\n      The duration of the clinical phase was approximately 19 days including washout period of 15\n      days between administrations of study drug in each study period."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male and non pregnant female human subjects, age in the range of 18 - 45 years.\n\n          2. Body weight within \u00b1 15% of ideal weight as related to height and body frame\n             according to Life Insurance Corporation (LIC) Chart.\n\n          3. Subjects with normal findings as determined by baseline history, physical examination\n             and vital sign examination (blood pressure, pulse rate, respiration rate and axillary\n             temperature).\n\n          4. Subjects with clinically acceptable findings as determined by haemogram,\n             biochemistry, urinalysis and 12 lead ECG.\n\n          5. Willingness to follow the protocol requirements especially abstaining from xanthine\n             containing food or beverages (chocolates, tea, coffee or cola drinks) or grapefruit\n             juice, any alcoholic products,  the use of cigarettes and tobacco products for 48\n             hours prior to dosing until after the last blood sample collection in each study\n             period and adherence to food, fluid and posture restrictions.\n\n          6. No history of significant alcoholism.\n\n          7. No history of drug abuse (benzodiazepines and barbiturates) for the last one month\n             and other illegal drugs for the last 6 months.\n\n          8. Non-smokers were included.\n\n        Exclusion Criteria:\n\n          1. Known history of hypersensitivity to Lisinopril or related drugs.\n\n          2. Requiring medication for any ailment having enzyme-modifying activity in the previous\n             28 days, prior to dosing day.\n\n          3. Subjects who have taken prescription medications or over-the-counter products\n             (including vitamins and minerals) within 14 days prior to administration of\n             Investigational Product.\n\n          4. Any medical or surgical conditions, which might significantly interfere with the\n             functioning of gastrointestinal tract, blood-forming organs etc.\n\n          5. History of cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological,\n             metabolic, haematological, gastrointestinal, endocrine, immunological or psychiatric\n             diseases.\n\n          6. Participation in a clinical drug study or bioequivalence study 90 days prior to\n             present study.\n\n          7. History of malignancy or other serious diseases.\n\n          8. Blood donation 90 days prior to the commencement of the study.\n\n          9. Subjects with positive HIV tests, HBsAg or Hepatitis-C tests.\n\n         10. Found positive in breath alcohol test.\n\n         11. Found positive in urine test for drug abuse.\n\n         12. History of problem in swallowing.\n\n         13. Any contraindication to blood sampling.\n\n         14. Found positive serum Beta- hCG (Human Chorionic Gonadotropin) test.\n\n         15. Lactating women (currently breast feeding).\n\n         16. Female subjects not confirming to using birth control measures, from the date of\n             screening until the completion of the study. Abstinence, barrier methods (condom,\n             diaphragm, etc.) were acceptable. Use of hormonal contraceptives either oral or\n             implants.\n\n         17. Female subjects whose menstruation cycle coincided with the study periods."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01735318", 
            "org_study_id": "Ipca/ARL-10/384"
        }, 
        "intervention": [
            {
                "arm_group_label": "Lisinopril Tablets 40 mg", 
                "description": "40 mg tablet once a day", 
                "intervention_name": "Lisinopril Tablets 40 mg", 
                "intervention_type": "Drug", 
                "other_name": "Test Product"
            }, 
            {
                "arm_group_label": "Zestril\u00ae (Lisinopril) 40 mg Tablets", 
                "description": "40 mg tablet once a day", 
                "intervention_name": "Lisinopril", 
                "intervention_type": "Drug", 
                "other_name": "Zestril\u00ae (Lisinopril) 40 mg Tablets"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Lisinopril"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "November 30, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Navi-Mumbai", 
                    "country": "India", 
                    "state": "Maharashtra"
                }, 
                "name": "Accutest Research Lab (I) Pvt. Ltd."
            }
        }, 
        "location_countries": {
            "country": "India"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Balanced, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover, Bioequivalence Study of Lisinopril Tablets 40 mg With Zestril\u00ae (Lisinopril) 40 mg Tablets in Normal, Healthy, Adult, Male and Female Human Subjects Under Fasting Conditions.", 
        "overall_official": {
            "affiliation": "Accutest Research Lab (I) Pvt. Ltd.", 
            "last_name": "Dr. Suhas Khandave, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "India: Ministry of Health", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Sampling Hours: Pre-dose and at 1.00, 2.00, 3.00, 4.00, 5.00, 6.00, 6.25, 6.50, 6.75, 7.00, 7.25, 7.50, 7.75, 8.00, 8.50, 9.00, 10.00, 12.00, 16.00, 24.00, 48.00 and 72.00 hours post dose", 
                "measure": "Cmax", 
                "safety_issue": "No", 
                "time_frame": "2 months"
            }, 
            {
                "description": "Sampling Hours: Pre-dose and at 1.00, 2.00, 3.00, 4.00, 5.00, 6.00, 6.25, 6.50, 6.75, 7.00, 7.25, 7.50, 7.75, 8.00, 8.50, 9.00, 10.00, 12.00, 16.00, 24.00, 48.00 and 72.00 hours post dose", 
                "measure": "AUC", 
                "safety_issue": "No", 
                "time_frame": "2 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01735318"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "IPCA Laboratories Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "IPCA Laboratories Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}